Lilly to acquire Centessa Pharmaceuticals to advance treatments for sleep-wake disorders

Eli Lilly and Company logo. (PRNewsFoto, Eli Lilly and Company)

In the Phase 3 ADorable-1 study, 63% of patients achieved meaningful skin improvement (EASI-75) and 44% achieved clear or almost clear skin (IGA 0,1) at Week 16

In key secondary endpoints, 39% of patients achieved a high bar of near-complete skin clearance (EASI-90) and 35% achieved significant itch relief (Pruritus NRS ≥4-point improvement)

Recommended for you